Sino Biopharmaceutical Limited (FRA:SMZ1)

Market Cap	12.91B +98.2%
Revenue (ttm)	3.63B +13.2%
Net Income	460.14M +20.6%
EPS	0.03 +23.1%
Shares Out	n/a
PE Ratio	28.06
Forward PE	22.24
Dividend	0.01 (1.40%)
Ex-Dividend Date	Aug 29, 2025

Volume	n/a
Average Volume	6,265
Open	0.7090
Previous Close	0.7000
Day's Range	0.7090 - 0.7090
52-Week Range	0.3748 - 0.9926
Beta	n/a
RSI	50.11
Earnings Date	Mar 27, 2026

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 23,056
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SMZ1

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY